Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Maternal or obstetric deterioration
New hypertension, neurological symptoms, chest pain, dyspnoea, thrombosis, fever, reduced fetal movement, bleeding or rapidly active renal, cardiac, pulmonary or neurological rheumatic disease may threaten both mother and fetus.
Action: Arrange urgent obstetric and specialty assessment, stabilise the mother using pregnancy-compatible emergency treatment, investigate infection, pre-eclampsia, thrombosis and disease flare in parallel, and do not withhold organ-saving therapy solely because of pregnancy.
Synopsis
Plan conception and postnatal care around stable rheumatic disease, replace teratogenic medicines before pregnancy, continue compatible disease control, and coordinate maternal, placental, fetal and infant-vaccine monitoring.
Aim for stable low disease activity for about six months before conception, using medicines that can continue through pregnancy; active disease is itself a maternal and fetal exposure.
At preconception review define renal, cardiac, pulmonary and thrombotic risk, check blood pressure and urine, and test anti-Ro, anti-La and antiphospholipid antibodies when relevant.
Hydroxychloroquine, sulfasalazine with folic acid 5 mg daily, azathioprine, tacrolimus, ciclosporin, prednisolone, colchicine and TNF inhibitors can be compatible when clinically indicated.
Key red flags
Severe headache, visual disturbance, epigastric pain, hypertension, thrombocytopenia or increasing proteinuria requires urgent pre-eclampsia assessment even when lupus nephritis is also plausible.
Pre-eclampsia pattern
New hypertension after 20 weeks with proteinuria or maternal organ or placental dysfunction requires urgent maternity assessment and can coexist with lupus nephritis.
Investigation priorities
01
First-line preconception disease assessmentFirst stepFirst line
Define whether activity and organ reserve are safe enough for pregnancy.
Management branches
Preconception first-lineStabilise disease on compatible treatment
A person with rheumatic disease plans pregnancy but is not yet pregnant.
Assess activity and organ, thrombotic and obstetric history and aim for approximately six months of stable low disease activity before conception.
Continue or introduce compatible hydroxychloroquine, sulfasalazine, azathioprine, calcineurin inhibitor or TNF treatment appropriate to the disease.
Late biologic exposureProtect maternal control and plan infant vaccines
An Fc-containing biologic is needed beyond the gestation at which stopping would permit routine live vaccination.
Key medicines
HydroxychloroquineContinue 200–400 mg orally daily, keeping long-term dose at no more than 5 mg/kg actual body weight each day, throughout pregnancy and breastfeeding when clinically indicated.
Sulfasalazine with folic acidTitrate sulfasalazine to the effective rheumatology dose, commonly 2 g orally daily in divided doses, and give folic acid 5 mg orally daily during periconception and the first trimester.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.